Money

Found 79,340 articles

• Protagonist Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/4/2023

  Protagonist Therapeutics reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

• Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

  5/4/2023

  Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, provided a corporate update and announced its financial results for the first quarter ended March 31, 2023.

• NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

  5/4/2023

  NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases provided a business update and reported first quarter 2023 financial results.

• argenx Reports First Quarter 2023 Financial Results and Provides Business Update

  5/4/2023

  argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced its first quarter 2023 financial results and provided a business update.

• DBV Technologies Reports First Quarter 2023 Financial Results

  5/4/2023

  DBV Technologies, a clinical-stage biopharmaceutical company, reported financial results for the first quarter of 2023.

• SI-BONE Announces Launch of Public Offering of Common Stock - May 04, 2023

  5/4/2023

  SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced that it has commenced an underwritten public offering of 3,775,000 shares of its common stock.

• Curis Provides First Quarter 2023 Business Update

  5/4/2023

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its business update and financial results for the first quarter ended March 31, 2023.

• Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023

  5/4/2023

  Blueprint Medicines Corporation announced that, effective May 1, 2023, the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 18,300 shares of its common stock and an aggregate of 9,146 restricted stock units to eleven new employees under Blueprint Medicines' 2020 Inducement Plan.

• Collegium Reports First Quarter 2023 Financial Results

  5/4/2023

  Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, reported its financial results for the quarter ended March 31, 2023, and provided a corporate update.

• Panbela Provides Business Update and Reports Q1 2023 Financial Results

  5/4/2023

  Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, provides a business update and reports financial results for the quarter ended March 31, 2023.

• IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow

  5/4/2023

  IntelGenx Technologies Corp., a leader in pharmaceutical films, announced that it will release its first quarter 2023 financial results after market close on Thursday, May 11, 2023.

• Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 04, 2023

  5/4/2023

  Syndax Pharmaceuticals, Inc. announced that on May 1, 2023 the Company granted inducement awards to purchase up to 272,000 shares of common stock to fifteen new employees under the Company's 2023 Inducement Plan.

• Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2023

  5/4/2023

  Galera Therapeutics, Inc. announced that on May 1, 2023, the Compensation Committee of Galera’s board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 315,000 shares of its common stock to three new employees.

• Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

  5/4/2023

  Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, reported financial results for the first quarter ended March 31, 2023 and reaffirmed guidance for full year 2023.

• Extendicare Announces 2023 First Quarter Results

  5/4/2023

  Extendicare Inc. reported results for the three months ended March 31, 2023.

• Globus Medical Reports First Quarter 2023 Results

  5/4/2023

  Globus Medical, Inc., a leading musculoskeletal solutions company, announced its financial results for the quarter ended March 31, 2023.

• Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates

  5/4/2023

  Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, reported financial results and provided business updates for the first quarter of 2023.

• Puma Biotechnology Reports First Quarter Financial Results

  5/4/2023

  Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2023.

• DermTech Reports First-Quarter 2023 Financial Results

  5/4/2023

  Covered lives increased to 126 million Cash runway through the third quarter of 2024 DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, reported its first-quarter 2023 financial results.

• Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results

  5/4/2023

  Aligos Therapeutics, Inc. reported recent business progress and financial results for the first quarter 2023.